Physician
Lakeside North Family Medicine, LLC
Lakeside North Family Medicine, LLC was paid $401K by Medicaid between Aug 2021 and Dec 2024, across 24 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoLAKESIDE NORTH FAMILY MEDICINE, LLC
GUNTERSVILLE, AL 35976
GUNTERSVILLE, AL 35976
33aNPI1245809896assigned 06/18/2021
33bProvider typeFamily Medicine Physician
28Total paid$401K
24GClaims10,825
24DCodes billed24
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Alabama
Rank by total paid#96 of 455
Median peer was paid$57K
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,399 | $53K | |
| 2022 | 5,888 | $196K | |
| 2023 | 3,283 | $134K | |
| 2024incomplete | 255 | $19K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 2,506 | 1,892 | $114K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 22% | 711 | 508 | $88K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.2% | 1,009 | 855 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.6% | 1,014 | 742 | $34K |
| 87631 | 6.4% | 605 | 428 | $26K | |
| 87428 | 5.6% | 578 | 507 | $22K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.1% | 194 | 172 | $12K |
| 87486 | 2.9% | 680 | 495 | $11K | |
| 87581 | 2.8% | 677 | 492 | $11K | |
| 87640 | 2.5% | 752 | 550 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.3% | 43 | 41 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.8% | 690 | 454 | $7K |
12 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 1.1% | 53 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 634 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 46 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 66 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 35 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 73 | $853.24 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 71 | $736.24 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 56 | $650.98 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 112 | $465.27 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 22 | $421.92 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 186 | $180.84 |
| 81003 | <1% | 12 | $18.46 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCAMPBELL, DAVID (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Journey Treatment Center | Cottonwood Heights, UT | $1.86M |
| DR. Campbell's Century Dental Office, DR. Campbell, DDS, INC. | Altadena, CA | $743K |
| Institute for Research and Education in Family Medicine | Saint Louis, MO | $400K |
| Ear, Nose and Throat of Michiana P.C. | Granger, IN | $307K |
| Rural Health Care Innovations | Allen, OK | $201K |
| Threehorn LTD. Co. | Walhalla, SC | $180K |
| DR. Campbell's Century Dental | Inglewood, CA | $163K |
| Lakeside North Family Medicine, LLC | Guntersville, AL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.